<DOC>
	<DOCNO>NCT01596517</DOCNO>
	<brief_summary>The purpose study investigate efficacy effectiveness peginterferon alfa-2a ribavirin therapy Korean chronic hepatitis C patient .</brief_summary>
	<brief_title>Efficacy Effectiveness PegInterferon Ribavirin Korean Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>A retrospective analysis prospective , multicenter , industry-sponsored , open-label , uncontrolled , community-based clinical trial combination peginterferon alfa-2a ribavirin ( Pegasys Expanded Access Program ) conduct 6 tertiary referral center Korea 2003 2004 cohort hepatitis C patient treat single tertiary referral hospital ( Asan Medical Center , Seoul , Korea ) 2004 2008</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult age 1870 year serum antiHCV antibody ( + ) HCV RNA detectable PCR compensate liver disease ( ChildPugh class A ) HCV genotype 1 , 2 , 3 acute hepatitis C decompensated cirrhosis hepatocellular carcinoma liver disease hepatitis A B , autoimmune hepatitis HIV Ab ( + ) severe depression psychiatric disease previous organ transplantation absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm3 platelet count &lt; 75,000 cells/mm3 , hemoglobin ( Hb ) &lt; 13 g/dL men , &lt; 12 g/dL woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>